Abstract
In clinical trials a single dose of the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine has shown a rapid antidepressant effect in patients with treatment-resistant depression and bipolar depression. The implications of glutaminergic mechanisms in depression and the rapid effect of a single dose of ketamine could open new pathways to understand the pathophysiology of depression and the development of novel rapid-acting antidepressant drugs.
| Bidragets oversatte titel | Ketamine for treatment of acute depression |
|---|---|
| Originalsprog | Dansk |
| Tidsskrift | Ugeskrift for Laeger |
| Vol/bind | 175 |
| Udgave nummer | 37 |
| Sider (fra-til) | 2090-3 |
| Antal sider | 4 |
| ISSN | 0041-5782 |
| Status | Udgivet - 9 sep. 2013 |
| Udgivet eksternt | Ja |
Emneord
- Acute Disease
- Analgesics, Short-Acting/administration & dosage
- Anesthetics, Dissociative/administration & dosage
- Antidepressive Agents/administration & dosage
- Bipolar Disorder/drug therapy
- Depressive Disorder/drug therapy
- Excitatory Amino Acid Antagonists/administration & dosage
- Humans
- Ketamine/administration & dosage
- Placebos
- Psychiatric Status Rating Scales
- Randomized Controlled Trials as Topic
- Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors
- Treatment Outcome